Biotinylated SARS-CoV-2 Spike RBD Alpha Variant

Product Description

Biotinylated SARS-CoV-2 Spike RBD Alpha Variant
Catalog number: B2010501
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 ug
Molecular Weight or Concentration: 27 kDa
Supplied as: Lyophilized Powder
Applications: molecular component of many serological and antigenic assays for SARS-CoV-2 and its variants
Storage: -20℃
Keywords: Alpha Variant Spike, B.1.1.7 Spike RBD, Alpha RBD, biotin ALPHA RBD
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Wilson P, Changrob S, Fu Y, Guthmiller J, Halfmann P, Li L, Stamper C, Dugan
H, Accola M, Rehrauer W, Zheng NY, Huang M, Wang J, Erickson S, Utset H, Graves
H, Amanat F, Sather DN, Krammer F, Kawaoka Y. Cross neutralization of emerging
SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on
spike. Res Sq [Preprint]. 2021 Jul 19:rs.3.rs-678247.

2: Sinegubova MV, Orlova NA, Kovnir SV, Dayanova LK, Vorobiev II. High-level
expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably
transfected CHO cells by the EEF1A1-based plasmid vector. PLoS One. 2021 Feb
2;16(2):e0242890.

3: Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And
Novel Therapeutics Against Coronavirus (COVID-19). 2021 Jul 18. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.

4: Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH,
Composto K, Chow KF, Kordalewska M, Corvelo A, Oschwald DM, Fennessey S,
Zetkulic M, Dar S, Kramer Y, Mathema B, Germer S, Stone M, Simmons G, Busch MP,
Maniatis T, Perlin DS, Kreiswirth BN. Emergence of Multiple SARS-CoV-2 Antibody
Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma
Treatment. mSphere. 2021 Aug 25;6(4):e0048021.

5: Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P,
Navarro MJ, Lai L, Edara VV, Röltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn
S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M,
Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C,
Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA,
Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O’Hagan DT,
Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S,
Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport
J, Suthar MS, King NP, Veesler D, Pulendran B. Adjuvanting a subunit COVID-19
vaccine to induce protective immunity. Nature. 2021 Jun;594(7862):253-258.

6: Zhang Z, Zeng E, Zhang L, Wang W, Jin Y, Sun J, Huang S, Yin W, Dai J, Zhuang
Z, Chen Z, Sun J, Zhu A, Li F, Cao W, Li X, Shi Y, Gan M, Zhang S, Wei P, Huang
J, Zhong N, Zhong G, Zhao J, Wang Y, Shao W, Zhao J. Potent prophylactic and
therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection
in vivo. Cell Discov. 2021 Aug 12;7(1):65.

7: Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants
of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit
recombinant vaccines. Braz J Infect Dis. 2021 Aug 17;25(4):101606.

8: Calvignac-Spencer S, Budt M, Huska M, Richard H, Leipold L, Grabenhenrich L,
Semmler T, von Kleist M, Kröger S, Wolff T, Hölzer M. Rise and Fall of SARS-
CoV-2 Lineage A.27 in Germany. Viruses. 2021 Jul 29;13(8):1491.

9: Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, Lürken K,
Beigel A, Wrenger E, Lonnemann G, Cossmann A, Stankov MV, Dopfer-Jablonka A,
Kaiser PD, Traenkle B, Rothbauer U, Krause G, Schneiderhan-Marra N, Behrens GMN.
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on
haemodialysis. EBioMedicine. 2021 Aug;70:103524.
10: Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y,
Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H,
Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L,
Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. The
neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal
antibodies is retained against viral variants. Cell Rep. 2021 Aug 21:109679.

Products Related to Biotinylated SARS-CoV-2 Spike RBD Alpha Variant : SARS-CoV-2